Teton Advisors Inc. trimmed its position in BioTelemetry Inc (NASDAQ:BEAT) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,000 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Teton Advisors Inc. owned 0.39% of BioTelemetry worth $6,308,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in BioTelemetry by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after acquiring an additional 39,722 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in BioTelemetry by 1.8% during the 1st quarter. State of Alaska Department of Revenue now owns 11,327 shares of the medical research company’s stock worth $709,000 after acquiring an additional 195 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in BioTelemetry by 40.2% during the 1st quarter. Meeder Asset Management Inc. now owns 2,491 shares of the medical research company’s stock worth $154,000 after acquiring an additional 714 shares in the last quarter. Brinker Capital Inc. acquired a new position in BioTelemetry during the 1st quarter worth approximately $617,000. Finally, Avalon Advisors LLC acquired a new position in BioTelemetry during the 1st quarter worth approximately $2,052,000. Institutional investors and hedge funds own 90.84% of the company’s stock.
BEAT has been the subject of several analyst reports. BidaskClub cut shares of BioTelemetry from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 23rd. ValuEngine cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, July 18th. Dougherty & Co restated a “buy” rating and issued a $75.00 target price (down previously from $81.00) on shares of BioTelemetry in a report on Friday, April 26th. Lake Street Capital set a $90.00 target price on shares of BioTelemetry and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Zacks Investment Research cut shares of BioTelemetry from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $72.57.
BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, July 30th. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.08. BioTelemetry had a net margin of 11.06% and a return on equity of 22.98%. The business had revenue of $111.80 million during the quarter, compared to analysts’ expectations of $111.11 million. During the same quarter in the prior year, the business posted $0.46 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts expect that BioTelemetry Inc will post 1.98 EPS for the current year.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.